Wako, Japan

Akihiro Ogura



Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akihiro Ogura: Innovator in Albumin-Sugar Chain Complex Technology

Introduction

Akihiro Ogura is a notable inventor based in Wako, Japan. He has made significant contributions to the field of biochemistry, particularly through his innovative work on albumin-sugar chain complexes. His research aims to enhance the stability and functionality of these complexes within the body.

Latest Patents

Ogura holds a patent for an albumin-sugar chain complex. The objective of this invention is to provide a complex that is bound with a sufficient number of sugar chains to achieve a clustering effect while maintaining stability in the body. The patent describes an albumin-sugar chain complex that has five or more molecules of an asparagine-linked sugar chain bound per molecule of albumin. This complex serves as a carrier for selectively delivering functional molecules to target tissues in the body. Additionally, it can be utilized as a bioimaging probe, administered into the body of an animal.

Career Highlights

Throughout his career, Akihiro Ogura has worked with prominent companies in the biotechnology sector. He has been associated with Glytech, Inc. and Riken Corporation, where he has contributed to various research and development projects. His work has been instrumental in advancing the understanding and application of sugar chain complexes in medical science.

Collaborations

Ogura has collaborated with esteemed colleagues, including Katsunori Tanaka and Yasuyoshi Watanabe. These partnerships have fostered innovation and have led to significant advancements in their respective fields.

Conclusion

Akihiro Ogura's contributions to the field of biochemistry, particularly through his patent on albumin-sugar chain complexes, highlight his role as an influential inventor. His work continues to pave the way for advancements in targeted drug delivery and bioimaging technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…